Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Operating Leases (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Operating Leases for 2 consecutive years, with $17.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases fell 8.57% to $17.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $17.4 million, a 8.57% decrease, with the full-year FY2024 number at $18.6 million, changed N/A from a year prior.
  • Operating Leases was $17.4 million for Q3 2025 at Pyxis Oncology, down from $17.8 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $19.8 million in Q1 2024 to a low of $17.4 million in Q3 2025.